At the news
? BULLISHIMPACT 6/10 8-K filed Jul 20, 2026 at 09:03 ET
Oncolytics Biotech announced FDA Fast Track Designation for pelareorep in combination with a checkpoint inhibitor for second-line and later anal cancer (SCAC). This is the third Fast Track designation in gastrointestinal cancers, supporting a registrational pathway in an indication with no FDA-approved therapies and an estimated $1 billion U.S. market opportunity.
- FDA granted Fast Track Designation for pelareorep + checkpoint inhibitor in inoperable, locally recurrent or metastatic SCAC after prior systemic therapy.
- Third Fast Track designation in GI cancers (colorectal, pancreatic, anal).
- GOBLET study data: ORR ~30%, median DOR ~15.5 months, 12-month OS 82% vs 45.7% historical.
- No FDA-approved therapies exist for patients progressing after first-line standard of care in SCAC.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access